

STELARA® Biosimilars: Food and Drug Administration (FDA)-Approved Ustekinumab Biosimilars for Prescribing

Preferred Biosimilar Options

- PYZCHIVA™ (ustekinumab-ttwe)
- SELARSDI™ (ustekinumab-aekn)
- YESINTEK™ (ustekinumab-kfce)

These products are FDA-approved biosimilars to STELARA® (ustekinumab) and may be prescribed for eligible patients requiring ustekinumab therapy.

Why Prescribe a Biosimilar?

- ✓ Same mechanism of action as STELARA® (IL-12/IL-23 inhibitor)
- ✓ No clinically meaningful differences in safety, purity, or potency compared with STELARA®
- ✓ FDA-approved based on rigorous analytical, pharmacokinetic, and clinical evaluation
- ✓ Supports patient access to ustekinumab therapy

Prescribing Information

For members starting therapy, the biosimilar is required for the induction (initial) dose. Refer to [Biosimilar Utilization Management Strategy Policy](#) on parklandhealthplan.com. When prescribing, please include:

- Product name (PYZCHIVA™, SELARSDI™, or YESINTEK™)
- Diagnosis/indication
- Strength and dosing regimen
- Relevant clinical documentation, if required for coverage review

FDA-Approved Indication Summary of Preferred Biosimilars

Indication	PYZCHIVA™	SELARSDI™	YESINTEK™
Plaque Psoriasis (Adults)	✓	✓	✓
Plaque Psoriasis (Pediatric ≥6 Years)	✓	✓	✓
Psoriatic Arthritis (Adults)	✓	✓	✓
Psoriatic Arthritis (Pediatric ≥6 Years)	✓	✓	✓
Crohn's Disease (Adults)	✓	✓	✓
Ulcerative Colitis (Adults)	✓	✓	✓